Taysha Gene Therapies, Inc.TSHAEarnings & Financial Report
Nasdaq
TSHA Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-34.0M
Net Profit
$-32.7M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.09
Taysha Gene Therapies, Inc. Q3 2025 Financial Summary
Taysha Gene Therapies, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-32.7M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-32.7M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Taysha Gene Therapies, Inc. Annual Revenue by Year
Taysha Gene Therapies, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $8.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $8.3M |
| 2023 | $15.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M | $3.4M | $1.1M | $1.8M | $2.0M | $2.3M | $2.0M | $0 |
| YoY Growth | N/A | -27.5% | -53.6% | -62.3% | -43.9% | -32.5% | 78.6% | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $172.7M | $153.0M | $200.4M | $180.2M | $160.4M | $138.4M | $333.3M | $316.6M |
| Liabilities | $97.8M | $99.2M | $91.5M | $91.4M | $88.8M | $83.3M | $84.6M | $97.6M |
| Equity | $74.9M | $53.8M | $108.9M | $88.8M | $71.5M | $55.1M | $248.7M | $219.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-16.1M | $-19.8M | $-21.5M | $-21.6M | $-18.3M | $-22.0M | $-20.2M | $-24.2M |